Drug Profile
Deucravacitinib - Bristol-Myers Squibb
Alternative Names: BMS-986165; BMS-986165-01; SotyktuLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles; Urologics
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Plaque psoriasis
- Registered Erythrodermic psoriasis; Pustular psoriasis
- Phase III Psoriasis; Psoriatic arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Phase II Alopecia areata; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Hidradenitis suppurativa; Lupus nephritis; Ulcerative colitis
- No development reported Autoimmune disorders; Inflammatory bowel diseases
Most Recent Events
- 26 Dec 2023 Bristol-Myers Squibb completes a phase-II clinical trials in Ulcerative colitis (Treatment-experienced, Treatment-resistant) in USA, Canada, Netherlands, Poland, Puerto Rico, United Kingdom, Australia, Germany (PO) (NCT04613518)
- 13 Nov 2023 Phase-II clinical trials in Hidradenitis suppurativa in USA (PO) (NCT05997277)
- 10 Nov 2023 Pooled efficacy data from POETYK PSO-1 and POETYK PSO-2 phase-II trial in Psoriatic arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)